Legal & General Group
DMRA

Legal & General Group’s Damora Therapeutics DMRA Stock Holding History

Legal & General Group’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$821K Buy
+31,551
New +$764K ﹤0.01% 2255

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Legal & General Group's DMRA Position: Q2 2026 in Review

Legal & General Group opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 31,551 shares worth $821K. The stake represents ﹤0.01% of the portfolio and ranks #2255 among its holdings.

104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Legal & General Group held 31,551 shares of Damora Therapeutics worth $821K as of Q2 2026.
  • Damora Therapeutics was a new Legal & General Group position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2255 holding.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.